Clopidogrel Can Cause Hematospermia, Especially When Combined with Aspirin
Yes, clopidogrel 75 mg daily can cause hematospermia in your patient with polycythemia vera who is already on low-dose aspirin, and this combination significantly increases bleeding risk compared to aspirin alone.
The Bleeding Risk is Real and Additive
The FDA drug label explicitly lists hematuria as a more frequent bleeding event with clopidogrel 111. While hematospermia is not specifically listed, it represents genitourinary bleeding from the same antiplatelet mechanism. More importantly, dual antiplatelet therapy with clopidogrel plus aspirin increases bleeding time synergistically - from 7.6 minutes on aspirin alone to 17.5 minutes when clopidogrel is added 2. This represents more than a doubling of bleeding time.
The CURE trial data in the FDA label shows that clopidogrel plus aspirin causes:
- Major bleeding in 3.7% vs 2.7% with aspirin alone
- Minor bleeding in 5.1% vs 2.4% with aspirin alone
- Specifically increased rates of epistaxis, hematuria, and bruising 11
Why This Matters in Polycythemia Vera
Your patient has polycythemia vera, where low-dose aspirin (100 mg daily) is the standard of care for thrombosis prevention 34. The guidelines are clear that aspirin alone is effective - the European Collaboration on Low-dose Aspirin in Polycythemia Vera trial demonstrated that aspirin 100 mg/d prevents thrombotic complications even with elevated platelet counts 3.
Adding clopidogrel to aspirin in PV is not standard therapy and dramatically increases bleeding risk without established benefit in this population. The 2003 Mayo Clinic guideline specifically notes that higher-dose aspirin (900 mg/d) with dipyridamole increased gastrointestinal bleeding without thrombosis benefit 4. While lower-dose aspirin (40-100 mg/d) is safe, adding a second antiplatelet agent reintroduces this bleeding risk.
Clinical Decision Algorithm
If the patient is experiencing hematospermia:
- Stop the clopidogrel immediately - it is likely not indicated for PV alone
- Continue aspirin 100 mg daily - this is guideline-recommended for PV 34
- Ensure hematocrit is controlled to <45% with phlebotomy 45
- Monitor for resolution of hematospermia over 5-7 days (clopidogrel's platelet effect lasts the lifespan of affected platelets)
If clopidogrel was added for a specific indication (e.g., recent coronary stent):
- Recognize you are accepting significantly increased bleeding risk
- The hematospermia is an expected consequence of dual antiplatelet therapy
- Consider whether the cardiovascular indication truly requires dual therapy or if aspirin alone suffices
- If dual therapy is mandatory, counsel the patient that genitourinary bleeding (including hematospermia) is a known adverse effect
Key Pitfall to Avoid
Do not assume that because aspirin alone is well-tolerated in PV, adding clopidogrel will be similarly safe. Research shows that adverse hematological effects are significantly greater with combination therapy - reductions in hemoglobin, hematocrit, and blood cell counts are all more pronounced with dual therapy 6. The bleeding risk is not simply additive but synergistic 2.
The absolute annual increase in major bleeding from aspirin alone is modest (0.13%), but this increases substantially when clopidogrel is added 7. In a patient with PV who already has abnormal hematopoiesis and potential for thrombocytosis, this bleeding risk is magnified.